SP Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

SP Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.84M	Sell	41,213 -360	-0.9%	-$61.9K	0.63%	34
2026 Q1	$7.02M	Sell	41,573 -762	-2%	-$130K	0.62%	32
2025 Q4	$7.14M	Sell	42,335 -212	-0.5%	-$34.4K	0.56%	33
2025 Q3	$6.14M	Sell	42,547 -4,593	-10%	-$627K	0.49%	36
2025 Q2	$5.96M	Sell	47,140 -4,050	-8%	-$497K	0.49%	39
2025 Q1	$6.55M	Sell	51,190 -1,846	-3%	-$250K	0.58%	39
2024 Q4	$7.01M	Buy	53,036 +21	+0%	+$2.95K	0.59%	35
2024 Q3	$7.72M	Buy	53,015 +71	+0.1%	+$10.3K	0.64%	35
2024 Q2	$7.27M	Sell	52,944 -2,623	-5%	-$350K	0.66%	33
2024 Q1	$7.62M	Sell	55,567 -280	-0.5%	-$38.2K	0.71%	34
2023 Q4	$7.59M	Buy	55,847 +4,811	+9%	+$587K	0.78%	29
2023 Q3	$6.24M	Sell	51,036 -226	-0.4%	-$28.7K	0.7%	33
2023 Q2	$6.51M	Buy	51,262 +2	+0%	+$260	0.73%	33
2023 Q1	$6.62M	Sell	51,260 -10,260	-17%	-$1.34M	0.81%	32
2022 Q4	$8.08M	Buy	61,520 +2,094	+4%	+$271K	1.08%	30
2022 Q3	$6.95M	Buy	59,426 +4,235	+8%	+$526K	0.95%	29
2022 Q2	$6.49M	Buy	55,191 +4,544	+9%	+$539K	0.83%	33
2022 Q1	$6.6M	Buy	50,647 +2,458	+5%	+$320K	0.71%	35
2021 Q4	$6.47M	Buy	48,189 +3,622	+8%	+$561K	0.65%	38
2021 Q3	$7.02M	Buy	44,567 +2,323	+5%	+$391K	0.73%	35
2021 Q2	$6.85M	Buy	42,244 +459	+1%	+$70.7K	0.75%	33
2021 Q1	$6.46M	Sell	41,785 -1,628	-4%	-$259K	0.8%	31
2020 Q4	$7.34M	Sell	43,413 -111	-0.3%	-$15.9K	1.01%	25
2020 Q3	$6.12M	Buy	43,524 +31,786	+271%	+$4.31M	0.94%	24
2020 Q2	$1.58M	Buy	+11,738	New	+$1.5M	0.33%	47
2020 Q1	–	Sell	-31,367	Closed	-$3.78M	–	81
2019 Q4	$3.78M	Buy	31,367 +333	+1%	+$37.2K	0.87%	27
2019 Q3	$3.09M	Sell	31,034 -3,051	-9%	-$319K	0.79%	30
2019 Q2	$3.72M	Buy	34,085 +25	+0.1%	+$2.66K	0.95%	26
2019 Q1	$3.81M	Buy	34,060 +161	+0.5%	+$17.7K	1.04%	27
2018 Q4	$3.27M	Buy	33,899 +10,358	+44%	+$1.1M	1%	27
2018 Q3	$2.82M	Sell	23,541 -798	-3%	-$94K	0.8%	31
2018 Q2	$2.72M	Buy	+24,339	New	+$2.6M	0.74%	30

Other funds holding IBB

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

SP Asset Management's IBB Position: Q2 2026 in Review

SP Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 0.87% in Q2 2026, selling an estimated $61.9K and leaving 41,213 shares worth $7.84M. The position accounts for 0.63% of the portfolio, ranked #34.

SP Asset Management first reported a position in IBB in Q2 2018 and has held it in 32 quarters since. The position peaked at $8.08M in Q4 2022. 486 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

SP Asset Management held 41,213 shares of iShares Biotechnology ETF worth $7.84M as of Q2 2026.
SP Asset Management sold 360 iShares Biotechnology ETF shares in Q2 2026, an estimated $61.9K.
iShares Biotechnology ETF made up 0.63% of SP Asset Management's portfolio in Q2 2026, its #34 holding.
SP Asset Management first reported a position in iShares Biotechnology ETF in Q2 2018 and has held it in 32 quarters since.
SP Asset Management's iShares Biotechnology ETF position peaked at $8.08M in Q4 2022.
486 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on SP Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.